A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

Trial Details

NCT ID
NCT05746897
Phase
PHASE1
Sponsor
Hefei TG ImmunoPharma Co., Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • NM1F Injection
  • Pembrolizumab injection
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Male or female subjects age ≥ 18 years at the time of informed consent.
  • Subjects with histologically or cytologically diagnosed unresectable locally advanced, or metastatic solid tumors, mainly but not limited to CRC, T…
  • Subjects must have at least 1 evaluable lesion as defined by response evaluation criteria in solid tumors (RECIST) v1.1.
  • ECOG PS of 0\~2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →